# ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

> **NCT02330549** · PHASE2 · COMPLETED · sponsor: **Tobira Therapeutics, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Prediabetic State
- Non-alcoholic Fatty Liver Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Cenicriviroc 150 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02330549
- **Lead sponsor:** Tobira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-17
- **Primary completion:** 2016-08-11
- **Final completion:** 2016-09-08
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02330549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02330549, "ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02330549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*